The pandemic provided the best and worst of times for smid-cap medtechs.
Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
The Cabana trial has finally reported, but the data are inconclusive.